Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report

Anticancer Research

Volumn 18, Issue 2 B, 1998, Pages 1237-1241

  Möller, Peter ^a,b   Wittig, Burghardt ^b   Schadendorf, Dirk ^c,d  

^a HUMBOLDT UNIVERSITY   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anti IL 2 antibodies; Melanoma; TIL

Indexed keywords

ANTIBODY; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; ANTIBODY TITER; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER IMMUNOTHERAPY; CASE REPORT; FEVER; HUMAN; HYPOTENSION; INTRATUMORAL DRUG ADMINISTRATION; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; TUMOR VOLUME;

DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 0031803128     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ferrone S: Melanoma, immune surveillance, and immunotherapy. J Clin Invest 93: 1351-1352, 1994.
2. Mackensen A, Carcelain G, Viel S et al: Direct evidence to support the immunosurveiliance concept in a regressive melanoma. J Clin Invest 93: 1391-1402, 1994.
3. Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor infiltrating lymphocytes and interleukin-2 in immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676-1680, 1988.
4. Yannelli JR, Hyatt C, McConnell S et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer 65: 413-421, 1996.
5. Keilholz U, Schlag P, Tilgen W et al: Regional adminstration of lymphokine-activated killer cells can be superior to intravenous application. Cancer 69: 2172-2175, 1992.
6. Ibayashi Y, Yamaki T, Kawahara T et al: Effects of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients. Neurol Med Chir Tokyo 33: 448-457, 1993.
7. Matteucci P, Tresoldi M, Chiesa G et al: Intrapleural adminstration of interleukin-2 and LAK cells in locally advanced non-small-cell lung cancer. A case report. Tumori 80: 246-250, 1994.
8. Hayakawa M Hatano T, Oganwa Y et al: Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of IL-2. Urol Int 53: 117-124, 1993.
9. Vaglini M, Belli F, Santinami M et al: Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metstases from limb cutaneous melanoma. Ann Surg Oncol 2: 61-70, 1995.
10. Furue M, Yamada N, Takahashi T et al: Immunotherapy for Stewart-Treves syndrome - Usefulness of intrapleural administration of tumor-infiltrating lymphocytes against massive pleural effusion caused by metastatic angiosarcoma. J Am Acad Dermatol 5: 899-903, 1994.
11. Goto S, Sakai S, Kera J et al: A case report of recurrent cervical cancer which responded to a combination of biological therapies. Eur J Gynaecol Oncol 15: 235-240, 1994.
12. Yuan Sheng Sun, Jurgovsky K, Möller P et al: Vaccination with 1L-12-gene modified autologous melanoma cells - Preclinical results and a first clinical phase I study -.(in submission).
13. Liu DL, Hakansson CH, Seifert J et al: Immunotherapy in liver tumors: II. Intratumoral injection with activated tumor-infiltrating lymphocytes, intrasplenic administration of recombinant interleukin-2 and interferon-alpha causes tumor regression and lysis. Cancer Letters 85: 39-46, 1994.
14. Cameron RB, Spiess PJ, Rosenberg SA et al: Synergistic antitumor activity of tumor infiltrating lymphocytes, interleukin-2 and local tumor irradiation: Studies on the mechanism of action. J Exp Med 171: 249-263, 1990.
15. Rubin JT, Elwood LJ, Rosenberg SA et al: Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res 49: 7086-7092, 1989.
16. Cameron RB, McIntosh JK, Rosenberg SA et al: Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid interferon-alpha in the treatment of established murine hepatic metastases. Cancer Res 48: 5810-5817, 1988.
17. Yang JC, Perry-Laaley D, Rosenberg SA et al: An improved method for growing murine tumor infiltrating lymphoxcytes with in vivo antitumor activity. J Biol Response Mod 9: 149-159, 1990.
18. Möller P, Yuan Sheng Sun, Dorbic T et al: Vaccination with IL-7-gene modified autologous melanoma cells can enhance the antimelanoma lytic activity in peripheral blood of patients with a good performance status - A clinical phase I study. Br J Cancer. in press.
19. Dummer R, Miller K, Eilles C et al: The Skin: An Immunoreactive target organ during interleukin-2 administration? Dermatologica 183: 95-99, 1991.
20. Scharenberg JGM, Stam AGM, von Bomberg BME et al. The development of anti-interleukin-2 (IL-2) antibodies in Cancer patients treated with recombinant IL-2. Eur J Cancer 304: 1804-1809, 1994.